Shares of ImmuPharma plc (LON:IMM – Get Free Report) were up 12.5% during trading on Friday . The stock traded as high as GBX 4.50 and last traded at GBX 4.50. 660,701 shares changed hands during trading, a decline of 75% from the average daily volume of 2,689,021 shares. The stock had previously closed at GBX 4.
ImmuPharma Stock Performance
The firm’s 50 day moving average price is GBX 4.21 and its two-hundred day moving average price is GBX 5.38. The company has a market cap of £28.08 million, a P/E ratio of -12.16 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last issued its earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 353.21% and a net margin of 3,519.56%. As a group, analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
